Ru Liu1, Xiao-Huan Zhang2, Kun Zhang2, Wei Li2, Wen-Jun Wang2, Di-Xian Luo3, Ling Gao2. 1. Department of Ophthalmology, the Second Xiangya Hospital Central South University, Changsha 410011, Hunan Province, China ; Department of Ophthalmology, the First People's Hospital of Chenzhou City, Chenzhou 423000, Hunan Province, China ; Institute of Translational Medicine, the First People's Hospital of Chenzhou City, Chenzhou 423000, Hunan Province, China. 2. Department of Ophthalmology, the Second Xiangya Hospital Central South University, Changsha 410011, Hunan Province, China. 3. Institute of Translational Medicine, the First People's Hospital of Chenzhou City, Chenzhou 423000, Hunan Province, China.
Abstract
AIM: To investigate the effect of 5-Aza-2'-deoxycytidine (5-Aza-CdR), a DNA methyltransferase (DNMT) inhibitor, on the growth and survival of the Chinese retinoblastoma (RB) cell line HXO-RB44. METHODS: The DNA methylation status of the Ras association domain family (RASSF1A) promoter in the presence of 5-Aza-CdR at different concentrations was analyzed by methylation-specific polymerase chain reaction (MSP). RASSF1A mRNA and protein levels were measured by semiquantitative RT-PCR and immunohistochemistry staining, respectively, when cells were treated with 5.0µmol/L of 5-Aza-CdR. The effect of 5.0µmol/L 5-Aza-CdR on the proliferation and viability of HXO-RB44 cells was examined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry. RESULTS: 5-Aza-CdR efficiently induced cell cycle arrest at G0/G1 and apoptotic death in HXO-RB44 cells. MSP analysis showed that unmethylated RASSF1A DNA increased and methylated RASSF1A decreased in a dose-dependent manner in a range of 0.5-5.0µmol/L 5-Aza-CdR. Accordingly, RASSF1A expression was reactivated at both mRNA and protein levels. Incubation time of 5-Aza-CdR treatment also functioned as a factor for the demethylation status of RASSF1A promoter DNA, with a plateau on day four. 5-Aza-CdR at 5.0µmol/L completely demethylated the RASSF1A promoter in HXO-RB44 cells on day four, and as a result, RASSF1A expression increased significantly from day 4 to day 7. CONCLUSION: 5-Aza-CdR inhibits the growth of the HXO-RB44 RB cell line and induces apoptosis by demethylating the RASSF1A gene.
AIM: To investigate the effect of 5-Aza-2'-deoxycytidine (5-Aza-CdR), a DNA methyltransferase (DNMT) inhibitor, on the growth and survival of the Chinese retinoblastoma (RB) cell line HXO-RB44. METHODS: The DNA methylation status of the Ras association domain family (RASSF1A) promoter in the presence of 5-Aza-CdR at different concentrations was analyzed by methylation-specific polymerase chain reaction (MSP). RASSF1A mRNA and protein levels were measured by semiquantitative RT-PCR and immunohistochemistry staining, respectively, when cells were treated with 5.0µmol/L of 5-Aza-CdR. The effect of 5.0µmol/L 5-Aza-CdR on the proliferation and viability of HXO-RB44 cells was examined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry. RESULTS: 5-Aza-CdR efficiently induced cell cycle arrest at G0/G1 and apoptotic death in HXO-RB44 cells. MSP analysis showed that unmethylated RASSF1A DNA increased and methylated RASSF1A decreased in a dose-dependent manner in a range of 0.5-5.0µmol/L 5-Aza-CdR. Accordingly, RASSF1A expression was reactivated at both mRNA and protein levels. Incubation time of 5-Aza-CdR treatment also functioned as a factor for the demethylation status of RASSF1A promoter DNA, with a plateau on day four. 5-Aza-CdR at 5.0µmol/L completely demethylated the RASSF1A promoter in HXO-RB44 cells on day four, and as a result, RASSF1A expression increased significantly from day 4 to day 7. CONCLUSION: 5-Aza-CdR inhibits the growth of the HXO-RB44 RB cell line and induces apoptosis by demethylating the RASSF1A gene.
Entities:
Keywords:
5-Aza-2′-deoxycytidine; Ras association domain family; apoptosis; methylation; retinoblastoma
Authors: Reena Shakya; Tamas Gonda; Michael Quante; Martha Salas; Samuel Kim; Jenna Brooks; Steffen Hirsch; Justine Davies; Angelica Cullo; Kenneth Olive; Timothy C Wang; Matthias Szabolcs; Benjamin Tycko; Thomas Ludwig Journal: Cancer Res Date: 2012-11-29 Impact factor: 12.701
Authors: Natalia Volodko; Mohamed Salla; Alaa Zare; El-Arbi Abulghasem; Krista Vincent; Matthew G K Benesch; Todd P W McMullen; Oliver F Bathe; Lynne Postovit; Shairaz Baksh Journal: Cancers (Basel) Date: 2016-06-10 Impact factor: 6.639